The US FDA granted OST-HER2 rare pediatric disease designation for osteosarcoma in 2021. The US FDA rare pediatric disease PRV program aims to incentivize drug development for rare pediatric diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback